National Heart, Lung, and Blood Institute; Notice of Closed Meeting, 47757 [2017-22141]
Download as PDF
<![CDATA[
47757
Federal Register / Vol. 82, No. 197 / Friday, October 13, 2017 / Notices
ESTIMATED ANNUALIZED BURDEN HOURS—Continued
Type of respondent
Form name
Number of
respondents
Number of
responses per
respondent
Average
burden per
response
(in hours)
Total
burden hours
State Government .......................................................
Federal Government ....................................................
20
10
1
1
5/60
5/60
2
1
Total ......................................................................
250
250
........................
105
Dated: October 6, 2017.
Karla Bailey,
Project Clearance Liaison, National Cancer
Institute, National Institutes of Health.
Dated: October 6, 2017.
Michelle Trout,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–22156 Filed 10–12–17; 8:45 am]
[FR Doc. 2017–22141 Filed 10–12–17; 8:45 am]
BILLING CODE 4140–01–P
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institutes of Health
Prospective Grant of Exclusive Patent
License: Devices and Systems For
Treating Valvular Regurgitation
National Heart, Lung, and Blood
Institute; Notice of Closed Meeting
asabaliauskas on DSKBBXCHB2PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
NHLBI Special Emphasis Panel.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel;
NHLBI Single Site CLTR Review.
Date: November 6, 2017.
Time: 8:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hyatt Regency Bethesda, One
Bethesda Metro Center, 7400 Wisconsin
Avenue, Bethesda, MD 20814.
Contact Person: Chang Sook Kim, Ph.D.,
Scientific Review Officer, Office of Scientific
Review/DERA, National Heart, Lung, and
Blood Institute, 6701 Rockledge Drive, Room
7188, Bethesda, MD 20892–7924, 301–827–
7940, carolko@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.233, National Center for
Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung
Diseases Research; 93.839, Blood Diseases
and Resources Research, National Institutes
of Health, HHS)
VerDate Sep<11>2014
18:05 Oct 12, 2017
Jkt 244001
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The National Heart, Lung and
Blood Institute (NHLBI), National
Institutes of Health, Department of
Health and Human Services, is
contemplating the grant of an Exclusive
Patent License to Cook Medical
Technologies, LLC, located in
Bloomington, Indiana, to practice the
inventions embodied in the patent
applications listed in the
Supplementary Information section of
this notice.
DATES: Only written comments and/or
applications for a license which are
received by the NHLBI Office of
Technology Transfer and Development
October 30, 2017 will be considered.
ADDRESSES: Requests for copies of the
patent applications, inquiries, and
comments relating to the contemplated
exclusive patent license should be
directed to: Michael Shmilovich, Esq.,
Senior Licensing and Patent Manager,
31 Center Drive Room 4A29, MSC2479,
Bethesda, MD 20892–2479, phone
number 301–435–5019, or shmilovm@
mail.nih.gov.
SUPPLEMENTARY INFORMATION: The
following and all continuing U.S. and
foreign patents/patent applications
thereof are the intellectual properties to
be licensed under the prospective
agreement to Cook Medical
Technologies, LLC: NIH Ref. No. E–027–
2013/0 ‘‘Devices And Methods for
Treating Functional Triscupid Valve
SUMMARY:
PO 00000
Frm 00071
Fmt 4703
Sfmt 4703
Regurgitation’’ U.S. Provisional Patent
Application 61/785,652 filed March 14,
2013, International Patent Application
PCT/US2014/025300 filed under the
Patent Cooperation Treaty on March 13,
2014, European Patent Application
14723540.2 having an international
filing date of March 13, 2014, and U.S.
Patent Application 14/776,488 also
having an international filing date of
March 13, 2014. NIH Ref. No. E–115–
2013/0 ‘‘Encircling Suture Delivery
System For Flexible Circumferential
Suture,’’ U.S. Provisional Patent
Application 61/834,357 filed June 12,
2013, International Patent Application
PCT/US2014/040716 filed under the
Patent Cooperation Treaty on June 3,
2014, European Patent Application
14735030.0 having an international
filing date of June 3, 2014 and U.S.
Patent Application 14/898,020 also
having an international filing date of
June 3, 2014. The patent rights in these
inventions have been assigned to the
Government of the United States of
America. The prospective exclusive
patent License territory may be
worldwide and a field of use limited to
valvular regurgitation.
The invention embodied in NIH Ref.
No. E–027–2013/0 relates to devices and
methods for treating functional
tricuspid valve regurgitation and related
conditions. The devices are adapted for
applying force to an area of a patient’s
heart along or near the atrioventricular
groove and can include a tensioning
element configured to be delivered by a
flexible member guided through a
catheter and positioned generally along
or near the atrioventricular groove, and
a compression member that can be
positioned along the tensioning element
and over a desired segment of the
atrioventricular groove to develop force
to be applied to an adjacent area of the
heart by selective tensioning of the
tensioning element.
The invention embodied in NIH Ref
No. E–115–2013/0 relates to devices for
delivering encircling implants that can
include two separate limbs held
together at a distal articulation by the
implant being delivered. The implant
can comprise a suture and/or a braided
E:\FR\FM\13OCN1.SGM
13OCN1
]]>Agencies
[Federal Register Volume 82, Number 197 (Friday, October 13, 2017)]
[Notices]
[Page 47757]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-22141]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood Institute; Notice of Closed
Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the NHLBI Special Emphasis Panel.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Heart, Lung, and Blood Institute
Special Emphasis Panel; NHLBI Single Site CLTR Review.
Date: November 6, 2017.
Time: 8:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Hyatt Regency Bethesda, One Bethesda Metro Center, 7400
Wisconsin Avenue, Bethesda, MD 20814.
Contact Person: Chang Sook Kim, Ph.D., Scientific Review
Officer, Office of Scientific Review/DERA, National Heart, Lung, and
Blood Institute, 6701 Rockledge Drive, Room 7188, Bethesda, MD
20892-7924, 301-827-7940, carolko@mail.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.233,
National Center for Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839,
Blood Diseases and Resources Research, National Institutes of
Health, HHS)
Dated: October 6, 2017.
Michelle Trout,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2017-22141 Filed 10-12-17; 8:45 am]
BILLING CODE 4140-01-P
